Kornimate/medical-research-clean huggingface dataset:
sexual dysfunction among inflammatory bowel disease adults-clinical trial

Conditions: Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis

Summary: patients with inflammatory bowel disease (ibd) have higher rates of sexual dysfunction than the general population. we offer an educational program on ibd including a specific discussion on intimacy and sexuality for ibd patients. our objective is to investigate the benefit of this intervention on sexual function in patients with ibd.

patients with inflammatory bowel disease (ibd) have higher rates of sexual dysfunction than healthy controls. no interventional study has addressed this matter so far. the aim of our study is to investigative the benefit of a psycho-educational intervention on sexual function in patients with ibd, by comparing patients participating to an educational program including a specific discussion on intimacy and sexuality to patients followed in usual care.

Eligibility criteria:
inclusion criteria: * age \> 18 years * crohn's disease or ulcerative colitis diagnosed according to usual criteria * participation to ibd educational program exclusion criteria: * unability to read or write french * patients without sexual activity for religious reasons

Keywords: inflammatory bowel disease crohn disease ulcerative colitis quality of life sexual function
a open-label study to evaluate the safety of trv130 in patients with acute pain

Conditions: Acute Pain

Summary: patients with moderate to severe pain caused by medical conditions or surgery, who require iv opioid therapy may be enrolled in this open label safety study. patients will be treated with trv130 by iv bolus, pca (patient-controlled analgesia) administration, or both, as determined by the investigator, for a duration not to exceed 14 days.

the duration of treatment for each patient will be determined by the clinical need for parenteral opioid therapy. eligible patients with moderate to severe pain caused by medical conditions or surgery, who require iv opioid therapy may be enrolled in this open label safety study. patients will be treated with trv130 by iv bolus, pca administration, or both, as determined by the investigator, for a duration not to exceed 14 days. the duration of treatment for each patient will be determined by the clinical need for parenteral opioid therapy. a follow-up assessment will take place 2-3 days after the completion of the treatment phase.

Eligibility criteria:
inclusion criteria include: * moderate to severe acute pain for which parenteral opioid therapy is warranted * able to understand and comply with the procedures and study requirements, and to provide written informed consent before any study procedure. exclusion criteria include: * clinically significant medical, surgical, postsurgical, psychiatric or substance abuse condition or history of such condition that would confound the interpretation of safety, tolerability, or efficacy data in the study. * hemodynamic instability or respiratory insufficiency. * advanced cancer in palliative or end-of-life care. * another current painful condition (other than acute pain for which parenteral opioid therapy is warranted) that would confound the interpretation of safety, tolerability, or efficacy data in the study. * clinically significant, immune-mediated hypersensitivity reaction to opioids.
thermal radiofrequency versus neurolytic saddle rhizotomyfor severe pereneal cancer pain

Conditions: Interactable Malignant Perineal Pain

Summary: the control of perineal malignant pain is difficult and challenging for pain physicians. different modalities have been tried to treat this complex pain syndrome including pharmacotherapy and interventional therapy. neuroaxial phenol rhizolysis is simple and cheap option. however; for patients with pelvic or rectal neoplasms and intact bowel and bladder sphincteric functions, there are neurosurgical recomendations of selective sacral nerve roots rhizotomy blockade "as an alternative to chemical saddle rhizotomy".

40 selected patients were randomly allocated into 2 groups "20 patients each" group 1 "rf group": in which patients underwent thermal radio frequency, selective (unilateral s3, bilateral s4 and s5) saddle rhizotomy. group 2 "phenol group": in which patients underwent hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin.

Eligibility criteria:
inclusion criteria: * cancer patients with moderate to severe perineal pain (vas \> 40mm over 100 mm scale). * intractable pain not responding to adequate tolerated opioid therapy + adjuvant therapy after reasonable period of time for at least 4 weeks (rad and kallmes, 2011). * limited life expectancy \< 12 months (slatakin etal 2003). * patients are continent to urine and stool (no stomas). exclusion criteria: * uncorrected coagulopathy. * local or systemic sepsis. * known allergy to the used medications. * distorted local anatomy e.g. by advanced local neoplastic growth rendering the procedure technically difficult or hazardous. * sign of increased intracranial tension (mintzer and devarajan, 2012).

Keywords: neuroaxial rhizolysis -selective rhizolysis-thermal radiofrequency
evaluation of the effectiveness of add-on hometreatment to family based therapy in adolescent anorexia nervosa.

Conditions: Anorexia in Adolescence

Summary: the project serves to evaluate a new treatment method with outreach services as a supplement to family-based therapy in the treatment of children and adolescents with eating disorders. the project is intended to help identify different family structures and which families will benefit most from the new outreach service of home-based treatment.


Eligibility criteria:
inclusion criteria: * children and adolescents aged 12 -20 years. * successful registrations in the special consultation for eating disorders at the clinic for child and adolescent psychiatry and psychotherapy (kjpp) of the psychiatric university hospital (puk) zurich. * diagnosis of anorexia nervosa or atypical anorexia nervosa (icd-10 f50.00/ f50.01/ f50.1) * existing informed consent of patients\* (14 years and older) and parents or legal guardians (12-14 years). * iq over 75 * resident in the canton of zurich * good knowledge of german exclusion criteria: * no written consent * children under 12 years * other forms of eating disorders apart from anorexia nervosa or atypical anorexia nervosa.
mechanisms of endothelial dysfunction in type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: endothelial dysfunction of conduit arteries plays an important role in the development of cardiovascular complications associated with type 2 diabetes. in order to propose targeted therapeutic approaches, this study aim to determine the mechanisms involved in endothelial dysfunction of conduit arteries in these patients.


Eligibility criteria:
inclusion criteria: - type 2 diabetic patients or control subjects or healthy volunteers exclusion criteria: * macroangiopathy * insulin treatment * chronic kidney disease (egfr\<60 ml/min/m²) * hyperlipidemia (total cholesterol\>2.5 g/l) * smoking habit \> 5 cigarettes/day * pregnancy
determination of the minimal concentration of antifibrinolytics required to inhibit t-pa-activated fibrinolysis

Conditions: Congenital Heart Disease; Fibrinolysis; Rotational Thromboelastometry

Summary: lysine analogs, like tranexamic acid (txa) or epsilon aminocaproic acid (eaca), are antifibrinolytic agents routinely administered in children undergoing different surgeries associated with a high bleeding risk (e.g. cardiac, craniofacial, and orthopedic surgeries). although there is a growing literature regarding the pharmacokinetic characteristics of these drugs in children, the plasmatic concentration required to completely inhibit fibrinolysis remains to be determined. in this in vitro study, the investigators will use an experimental model of fibrinolysis designed for rotational thromboelastometry (rotem®) to determine the minimal concentration inhibiting fibrinolysis for both txa and eaca. in addition, this study will be used to create and validate a new experimental assay to measure fibrinolysis and the effect of antifibrinolytic agents.


Eligibility criteria:
inclusion criteria: * infants between 2 months of age and equal to or less than 12 months of age * weigh over 5.0 kg * either have chd and are scheduled to undergo an elective cardiac catheterization lab procedure or do not have chd and are scheduled to undergo a non-cardiac surgery (such as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room exclusion criteria: * undergoing an emergent procedure, * child in a moribund condition (american society of anesthesiology (asa 5) * children with a hematological and/or oncological disease * jehovah witnesses * children with preoperative coagulopathy, defined as a platelet count \ 1.5 normal range
mra therapy versus cpap therapy in moderate osas

Conditions: Sleep Apnea, Obstructive

Summary: the purpose of this study is to compare the cost-effectiveness and effectiveness of mandibular repositioning appliance (mra) versus continuous positive airway pressure (cpap) therapy in patients with moderate obstructive sleep apnea syndrome (osas).

study design: in a randomized parallel controlled study 86 patients will be randomly assigned to either mra therapy or cpap therapy. group a receives mra. group b receives cpap. the total duration of the study is 12 months. measurements will be done at baseline, after 3, 6 and 12 months. intervention: group a will be treated with a bibloc mra (somnodent). the mandible will be set at 70% of the patient's maximum advancement and will be adjusted to the convenience of the patient. titration will be continued until symptoms abate or until further advancement causes discomfort. group b will be treated with cpap. proper cpap-pressure will be set for each patient separately. patients are fitted with a comfortable cpap mask before titration of the cpap-pressure. for cpap-titration, patients are instructed to adopt their own typical sleeping habits.

Eligibility criteria:
inclusion criteria: * individuals who have been subjected to polysomnography and are diagnosed as having moderate (ahi 15-30) osas; * aged ≥ 18 years; exclusion criteria: medical and psychological criteria: * patients previously treated for osas (e.g. cpap, mra); * morphologic abnormalities of the upper airway (e.g., a compromised nasal passage, enlarged tonsils or adenoids, or upper airway soft-tissue or craniofacial abnormality); * reported or documented unstable endocrine dysfunction (hypothyroidism, acromegaly, or pituitary adenoma); reported or documented severe cardiovascular- or pulmonary co-morbidity * clinically concurrent cardiovascular disease (coronary artery disease, heart failure,cardiac arrhythmias) * cva within 6 months prior to randomisation * daytime respiratory insufficiency * severe chronic obstructive pulmonary disease (copd) (gold 3 or 4; fev1 / fvc \< 70% and fev1 \< 50%); * other diseases that may impact the evaluation of the results of the study according to the investigator's judgement. * reported or documented psychological condition precluding informed consent (e.g., mental retardation, depression or schizophrenia); whether the patient has unstable endocrine dysfunction, severe cardiovascular- or pulmonary co-morbidity or a psychological condition precluding informed consent, will be assessed by evaluating the patient's medical record. dental exclusion criteria: * extensive periodontal disease or tooth decay; * active temporomandibular joint disease (including severe bruxism); * restrictions in mouth opening (\< 25mm) or advancement of the mandible \<5mm); * partial or complete edentulism (less than eight teeth in upper or lower jaw).

Keywords: cost-effectiveness effectiveness treatment cpap mra compliance
saccharomyces boulardii as pretreatment before rescue therapy of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: the increasing rate of drug resistance in often leads to eradication failure and the need for rescue therapy, and it is of great significance to explore new rescue therapeutic regimens. in this study, we observed the efficacy of rescue treatment of helicobacter pylori (h.pylori) with saccharomyces boulardii (s.boulardii) alone. the primary outcome of the trial was the eradication rate, and the secondary outcome was the incidence of adverse events.

background: helicobacter pylori(h.pylori)infection is a common bacterial infection that causes chronic gastritis, peptic ulcer, malt lymphoma, gastric cancer, and other gastrointestinal diseases. and has been classified as a group 1 biologic carcinogen with a prevalence of about 50% population in china. in recent years, with the massive use of antibiotics, poor patient compliance, and irregular drug use, the side effects associated with drugs have increased and have led to the development of antibiotic-resistant bacteria and a gradual increase in refractory h.pylori infections, researchers have been searching for a safe, effective and simple treatment for h. pylori. methods: the patient come from the department of gastroenterology, xiangya third hospital, central south university. after obtaining informed consent, patients is randomly divided into a study group and a control group. the study group (n=100) is divided into two stages of treatment, starting with saccharomyces boulardii monnotherapy for 14 days, patients who are still positive on reexamination after 4 weeks of stopping the drug continue with bismuth quadruple therapy. as for the control group (n=100), patients is observed for 4 weeks without any gastric drugs as well as antibiotics, and those who were still positive on retest after 4 weeks continued with bismuth quadruple therapy. we observe the eradication rate of patients and the occurrence of adverse effects during the treatment.

Eligibility criteria:
inclusion criteria: 1. aged 18 to 65 years, of either sex 2. patients with a diagnosis of hp infection 3. patients who have failed treatment for hp infection 4. not taking acid-suppressing medications (ppi or h2 blockers) within the last 2 weeks 5. who have not used antibiotics and/or bismuth within the last 4 weeks 6. understand and are willing to participate in this clinical trial and provide a signed informed consent form. exclusion criteria: 1. those with a history of drug allergy 2. those with severe cardiac, hepatic, pulmonary, and renal insufficiencies 3. those with a recent history of gastrointestinal hemorrhage, obstruction, perforation, tumors, and other serious organic diseases of the gastrointestinal tract 4. those with mental illness, psychological disorders that cannot be expressed normally 5. those who are pregnant, lactating, or planning to have children in the near future during the study period. 6. those who are not suitable for clinical trials and those who cannot cooperate

Keywords: saccharomyces boulardii helicobacter pylori rescue
phase 1 trial in patients with human papillomavirus (hpv)-associated cancer

Conditions: HPV Associated Cancers

Summary: this is an open-label, non-randomized, phase i, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic hpv-associated cancers. the expansion phase will begin in parallel one dose level lower than the highest dose deemed safe in the dose escalation in combination with a pd-1 checkpoint blockade.


Eligibility criteria:
inclusion criteria: * prior histologically confirmed hpv-associated squamous cell carcinoma, which is relapsed, resistant, or metastatic * life expectancy of at least 3 months * dose escalation phase: patients who have experienced disease progression on standard of care therapies exclusion criteria: * active cns metastases * have any history of seizure disorder or are taking prophylactic seizure medication * have an active viral, bacterial, or fungal infection
predictive factors of conversion in laparoscopic colorectal cancer resection

Conditions: Surgery; Colorectal Neoplasm; Laparoscopy

Summary: background laparoscopic resection is the treatment of choice for colorectal cancer. rates of conversion to open surgery range between 7% and 30% and controversy exists as to the effect of this on oncologic outcomes. the objective of this study was to analyze what factors are predictive of conversion and what effect they have on oncologic outcomes. material \& methods from a prospective database of patients undergoing laparoscopic surgery between 2000 and 2018 a uni- and multivariate analyses were made of demographic, pathological and surgical variables together with complementary treatments comparing purely laparoscopic resection with conversions to open surgery. overall and disease-free survival were compared using the kaplan-meier method.

laparoscopic resection of colorectal cancer is the surgical option of choice provided that established oncologic principles are guaranteed \[1-4\]. apart from the well-known advantages of minimally invasive surgery (shorter hospital stays, lower pain levels, faster return of bowel functions and rapid return to normal daily activities) reductions in operative morbidity and mortality have been reported together with oncologic outcomes which are similar to those of open surgery \[5-7\]. however, reported conversion rates to open surgery are highly variable (7% - 30%) as is the impact of conversion on oncologic outcomes \[8-10\]). the objectives of this study were to identify the risk factors associated with conversion and to assess their impact on operative morbidity and mortality and long-term oncologic outcomes.

Eligibility criteria:
inclusion criteria: * all laparoscopic colorectal neoplasia, laparoscopic resected exclusion criteria: * palliative and emergency procedures

Keywords: laparoscopic surgery, colorectal cancer
pre- versus post-incisional epidural morphine: higher postoperative pain perception and extra morphine consumption

Conditions: Pain

Summary: background and objectives: neuraxial administration of morphine is an effective way of controlling postoperative pain and reducing analgesic consumption. several animal models have demonstrated that preemptive administration of neuraxial narcotics reduced pain while others revealed the induction of post-incisional hypersensitivity. there have been no consistent results in clinical setting either. this double blind, randomized study compared the effects of pre- vs. post-incisional administration of neuraxial morphine on postoperative pain perception and analgesic requirements over 48 hours following laparotomy for open colectomy under standardized general anesthesia. methods: twenty patients received epidural morphine (3 mg) pre-incision and saline after wound closure (mo1 group), and 20 patients received epidural saline before incision and morphine after wound closure (mo2 group). postoperatively, all patients received boluses of morphine (1.5 mg) via intravenous patient-controlled analgesia (iv-pca), and rescue doses of intramuscular diclofenac (75 mg) every 6 hours, as needed.


Eligibility criteria:
inclusion criteria: 1.adults scheduled for elective laparotomy and colon surgery with the duration of surgery expected to last for at least 2 hours. exclusion criteria: 1. allergy to morphine, fentanyl, non-steroidal anti-inflammatory drugs or any of the intraoperative anesthetic medications 2. use of opioids, sedatives or stimulants during 21 days prior to surgery, psychiatric illness 3. congestive heart failure, respiratory failure, neuromuscular disease or presence of a chronic pain syndrome 4. pregnant women and patients unable to sign their own consent form

Keywords: epidural morphine preoperative postoperative analgesia tolerance preoperative, postoperative analgesia
development of aecopd identification tool (detect study)

Conditions: Acute Exacerbations of COPD

Summary: this study is an observational, multi-center and cross sectional study,to develop an identification tool on purpose of differentiating copd exacerbation from patients with respiratory symptoms in community hospitals of china.

this is an observational, multi-center and cross-sectional study to develop an aecopd identification tool. estimated totally 7 tertiary hospitals with experts in respiratory area will be involved as the study sites. these study sites will cover the regions of china (eastern, southern, northern, central, western and northeastern region), to be representative for the patient features all over the country. the patients will be enrolled in a "consecutive" way, which is, the investigators will recruit the patients who are eligible and consented to participate in this study without personal tendency. for the enrolled patients, a face to face visit between investigator and patient will be arranged. the evaluation for the symptoms and signs will be performed and the relevant data will be collected on the visit. in addition, other relevant tests (e.g. oxygen saturation, blood test, cat, etc) and data (demographic, medical history, etc) will be collected on this visit.

Eligibility criteria:
inclusion criteria: -≥ 40 years old of age. * able to adequately understand written and verbal * a signed and dated written informed consent must be obtained prior to the visits * patients see doctors due to suffering respiratory disease below: disease type 1 - diagnosed moderate and severe stable copd * patients with a diagnosis of copd and documented record with predicted ratio of fev1 to forced vital capacity (fvc) \< 0.70 before the study visit * copd with moderate to severe airflow obstruction (fev1\<0.8 predicted) disease type 2 - aecopd * patients with a diagnosis of copd and documented record with predicted ratio of fev1 to forced vital capacity (fvc) \< 0.70 before the study visit * patients consult the clinic or the emergency department because of acute worsening with an aecopd (diagnosed by more than 2 clinical experts and refer to diagnosis criteria of appendix 2) disease type 3 -non-copd patients with chronic respiratory symptoms such as cough, sputum and wheeze, dyspnea etc. (≥2 high risk factors ) exclusion criteria: * patients with severe cardiovascular disease, including uncontrolled hypertension with drug treatment, unstable angina, myocardial infarction within the last 6 months, nyha class ii congestive heart failure, severe arrhythmia, pericardial effusion, etc. * patients with lung cancer, esophageal cancer or mediastinal tumors; * patients who participated in any drug clinical trials within 4 weeks before enrollment; * patients with severe infection, indicated for intravenous antibiotics, antifungal or antiviral therapy; * patients suffering from mental illness and poor compliance; * patients inappropriate for inclusion decided by investigator.
effect of resistance training on jump landing mechanics in young female athletes

Conditions: Anterior Cruciate Ligament Injury

Summary: the purpose of this study is to determine if jump landing mechanics in young female athletes can be improved with a resistance training intervention.

after initial baseline testing, athletes were randomly selected to receive upper body (control group) or lower body (intervention group) resistance training. athletes attended supervised training sessions twice per week for 12 weeks, after which they were re-tested.

Eligibility criteria:
inclusion criteria: * at least one year experience playing organized sports exclusion criteria: * previous experience with resistance training * any injury with a pain level of more than 3/10 on vas * any health condition that would preclude them from completing the training or testing * previous experience using a biodex dynamometer

Keywords: resistance training